Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: A meta-analysis of 17 randomized controlled trials

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 849-861

  Liu, Lidan ^a   Cao, Yunfei ^a   Tan, Aihua ^a   Liao, Cun ^a   Gao, Feng ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Advanced or metastasis cancer; Cetuximab; Meta analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; NAVELBINE; OXALIPLATIN; PEMETREXED; PLACEBO; PLATINUM;

ACNE; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HEAD AND NECK CARCINOMA; HUMAN; HYPOMAGNESEMIA; INFECTION; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; CONTROL GROUPS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77649183418     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1090-x     Document Type: Article

References (43)

1. A Jemal R Siegel E Ward YP Hao JQ Xu T Murray MJ Thun 2008 Cancer statistics CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387
2. (2000) Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal meta-analysis collaboration. Cochrane Database Syst Rev (2):CD001545
3. PA Bunn 2002 Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20 23S 33S 12235221
4. PM Harari MA Ritter DG Petereit MP Mehta 2003 Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations Curr Probl Cancer 28 7 40 10.1016/j.currproblcancer.2003.10.002
5. FR Hirsch M Varella-Garcia PA Bunn Jr, et al. 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 3798 3807 10.1200/JCO.2003.11.069 12953099 (Pubitemid 46606235)
6. A Adenis E Aranda Aguilar YM Robin, et al. 2005 Expression of the epidermal growth factor receptor (EGFR or HER1) and human epidermal growth factor receptor 2 (HER2) in a large scale metastatic colorectal cancer (mCRC) trial J Clin Oncol 23 278s (suppl; abstr 3630)
7. MLH Fjallskog MH Lejonklou KE Oberg, et al. 2003 Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clin Cancer Res 9 1469 1473 12684421
8. J Mendelsohn J Baselga 2003 Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2787 2799 10.1200/JCO.2003.01.504 12860957 (Pubitemid 46606324)
9. O Dassonville JL Formento M Francoual, et al. 1993 Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1873 1878 8410112
10. K Liang KK Ang L Milas N Hunter Z Fan 2003 The epidermal growth factor receptor mediates radioresistance Int J Radiat Oncol Biol Phys 57 246 254 12909240
11. JA Bonner NJ Maihle BR Folven TJ Christianson K Spain 1994 The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities Int J Radiat Oncol Biol Phys 29 243 247 8195014
12. J Baselga 2001 The EGFR as a target for anticancer therapy-focus on cetuximab Eur J Cancer 37 suppl 4 S16 S22 10.1016/S0959-8049(01)00233-7 11597400
13. ES Kim FR Khuri RS Herbst 2001 Epidermal growth factor receptor biology (IMC-C225) Curr Opin Oncol 13 506 513 10.1097/00001622-200111000-00014 11673692 (Pubitemid 33027904)
14. CJ Bruns MT Harbison DW Davis, et al. 2000 Epidermal growth factor receptor blockade with C225 plus GEM results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms Clin Cancer Res 6 1936 1948 10815919
15. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 1201 1208 10.1200/JCO.2004.10.182 14993230 (Pubitemid 41079832)
16. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 10.1056/NEJMoa033025 15269313 (Pubitemid 38944402)
17. MKB Parmar V Torri L Stewart 1998 Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Statist Med 17 2815 2834 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID- SIM110>3.0.CO;2-8 (Pubitemid 28562978)
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 10655437
19. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F (2000) Methods for meta-analysis in medical research. Wiley, Chichester
20. LL Kjaergard J Villumsen C Gluud 2001 Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses Ann Intern Med 135 982 989 11730399
21. D Moher B Pham A Jones DJ Cook AR Jadad M Moher, et al. 1998 Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 609 613 10.1016/S0140-6736(98)01085-X 9746022 (Pubitemid 28380142)
22. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2008) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol [Epub ahead of print]
23. AF Sobrero J Maurel L Fehrenbacher W Scheithauer YA Abubakr MP Lutz ME Vega-Villegas C Eng EU Steinhauer J Prausova HJ Lenz C Borg G Middleton H Kroning G Luppi O Kisker A Zubel C Langer J Kopit HA Burris 3rd 2008 EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2311 2319 10.1200/JCO.2007.13.1193 18390971
24. DJ Jonker CJ O'Callaghan CS Karapetis JR Zalcberg D Tu HJ Au SR Berry M Krahn T Price RJ Simes NC Tebbutt G van Hazel R Wierzbicki C Langer MJ Moore 2007 Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2040 2048 10.1056/NEJMoa071834 18003960 (Pubitemid 350106711)
25. M Borner D Koeberle R Von Moos P Saletti D Rauch V Hess A Trojan D Helbling B Pestalozzi C Caspar T Ruhstaller A Roth A Kappeler D Dietrich D Lanz W Mingrone 2008 Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Ann Oncol 19 1288 1292 10.1093/annonc/mdn058 18349029 (Pubitemid 351911959)
26. J Tol M Koopman CJ Rodenburg A Cats GJ Creemers JG Schrama FL Erdkamp AH Vos L Mol NF Antonini CJ Punt 2008 A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity Ann Oncol 19 734 738 10.1093/annonc/mdm607 18272912
27. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25(36):5777-5784. Erratum in: J Clin Oncol 2008;26:3295
28. R Rosell G Robinet A Szczesna R Ramlau M Constenla BC Mennecier W Pfeifer KJ O'Byrne T Welte R Kolb R Pirker A Chemaissani M Perol MR Ranson PA Ellis K Pilz M Reck 2008 Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Ann Oncol 19 2 362 369 10.1093/annonc/mdm474 17947225 (Pubitemid 351201721)
29. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky KK Ang 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567 578 10.1056/NEJMoa053422 16467544 (Pubitemid 43209104)
30. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23(34):8646-8654. Erratum in: J Clin Oncol 2006;24:724
31. JB Vermorken R Mesia F Rivera E Remenar A Kawecki S Rottey J Erfan D Zabolotnyy HR Kienzer D Cupissol F Peyrade M Benasso I Vynnychenko D De Raucourt C Bokemeyer A Schueler N Amellal R Hitt 2008 Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 1116 1127 10.1056/NEJMoa0802656 18784101
32. S Cascinu R Berardi R Labianca S Siena A Falcone E Aitini S Barni F Di Costanzo E Dapretto G Tonini C Pierantoni S Artale S Rota I Floriani M Scartozzi A Zaniboni Italian Group for the Study of Digestive Tract Cancer (GISCAD) 2008 Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial Lancet Oncol 9 3 9 44 10.1016/S1470-2045(08)70042-1 (Pubitemid 351722935)
33. CJ Punt J Tol CJ Rodenburg A Cats G Creemers JG Schrama FL Erdkamp A Vos L Mol NF Antonini 2008 Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) J Clin Oncol 26 15S 10.1200/JCO.2007.15.9640
34. E Van Cutsem M Nowacki I Lang S Cascinu I Shchepotin J Maurel P Rougier D Cunningham J Nippgen C Kohne 2007 Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial J Clin Oncol 25 18S
35. R Pirker A Szczesna J von Pawel M Krzakowski R Ramlau K Park U Gatzemeier E Bajeta M Emig JR Pereira 2008 FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 26 20S 10.1200/JCO.2007.15.0748
36. J Bogart R Govindan X Wang D Liu RA Kratzke EE Vokes 2008 A phase II study of pemetrexed, carboplatin, thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-Early evaluation of feasibility, toxicity J Clin Oncol 26 20S 10.1200/JCO.2007.11.6905
37. PA Philip J Benedetti C Fenoglio-Preiser M Zalupski H Lenz E O'Reilly R Wong J Atkins J Abruzzese C Blanke 2007 Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study J Clin Oncol 25 18S 10.1200/JCO.2006.09.6040 (LBA4509) (Pubitemid 46596777)
38. BA Burtness ME Powell JD Berlin DK Liles AE Chapman EP Mitchell AB Benson 2008 Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: updated survival and CA19-9 results J Clin Oncol 26 20S 10.1200/JCO.2007.11.6905
39. CS Karapetis S Khambata-Ford DJ Jonker CJ O'Callaghan D Tu, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 10.1056/NEJMoa0804385 18946061
40. RM Touyz 2008 Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension Am J Physiol Heart Circ Physiol 294 H1103 H1118 10.1152/ajpheart.00903.2007 18192217
41. D Schrag KY Chung C Flombaum L Saltz 2005 Cetuximab therapy and symptomatic hypomagnesemia J Natl Cancer Inst 97 1221 1224 16106027
42. PI Rafailidis OK Kakisi K Vardakas ME Falagas 2007 Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials Cancer 109 2182 2189 10.1002/cncr.22666 17429839 (Pubitemid 46805005)
43. M Thomas 2005 Cetuximab: adverse event profile and recommendations for toxicity management CJON 9 332 338 10.1188/05.CJON.332-338